Amrutanjan Health Care Ltd. (BSE: 590006) is a Chennai, Tamil Nadu-based company in the Non-Prescription Drugs industry. With a market capitalisation of ₹1,467 Cr, it ranks #1,401 by market cap among the 6,197 Indian listed companies on FinBizNet, and #5 of 9 in Non-Prescription Drugs. At ₹507.50 (as of 16 Nov 2026), the share price is 30.1% below its 52-week high of ₹725.60 and 6.5% above its 52-week low of ₹476.50. The share price is down 28.1% over one year and up 3.4% over three months.
| Current Price | ₹507.50 |
|---|---|
| Market Cap | ₹1,467 Cr |
| BSE Code | 590006 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Non-Prescription Drugs |
| P/E Ratio | 25.3 |
| Return on Equity | 16.62% |
| Return on Assets | 8.47% |
| 52-Week Range | ₹476.50 – ₹725.60 |
| 1-Year Price Change | -28.1% |
| 3-Month Price Change | +3.4% |
| Beta (1Y) | 0.05 |
| Dividend Yield | 1.72% |
| Headquarters | Chennai, Tamil Nadu |
| Website | www.amrutanjan.com |
| Revenue | ₹135 Cr |
|---|---|
| Net Profit | ₹17 Cr |
| Net Margin | 12.8% |
| EPS (Basic) | ₹5.98 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Amrutanjan Health Care Ltd. reported revenue of ₹135 Cr in Q2 FY27, up 14.9% from ₹118 Cr in Q2 FY26 and up 31.3% from ₹103 Cr in Q1 FY27. It posted a net profit of ₹17 Cr for the quarter, against a net profit of ₹14 Cr in Q2 FY26 (up 23.8%). Across the 6 quarters from Q1 FY26 to Q2 FY27, quarterly revenue ranged from ₹94 Cr (Q1 FY26) to ₹150 Cr (Q4 FY26). The company was profitable in each of these 6 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹135 Cr | ₹17 Cr | 12.8% |
| Q1 FY27 | ₹103 Cr | ₹4 Cr | 4.2% |
| Q4 FY26 | ₹150 Cr | ₹16 Cr | 10.8% |
| Q3 FY26 | ₹141 Cr | ₹19 Cr | 13.8% |
| Q2 FY26 | ₹118 Cr | ₹14 Cr | 11.9% |
| Q1 FY26 | ₹94 Cr | ₹8 Cr | 8.8% |
Standalone figures (₹ crore, XBRL filings).
Promoters held 46.52% of Amrutanjan Health Care Ltd.'s shares as of Sept 2026, unchanged from Sept 2025. Delivery averaged 55.3% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Amrutanjan Health Care Limited manufactures, supplies, and sells ayurvedic pain balms and women hygiene products in India and internationally. It operates through OTC Products, Beverages, Women's Hygiene, and Others segments. The company provides pain management products comprising pain balms and roll-ons, back pain roll-ons, stick-on patch, and joint muscle sprays; dental pain gel; and decorn corn caps; hand sanitizer under the NOGerms brand name; and fruit and rehydration juice drinks under the Fruitnik brand name. The company also offers congestion management products that consists of cold rubs, cough syrups, nasal inhalers, and swas mints, as well as provides sanitary napkins for women. In addition, it operates a pain management center. The company was formerly known as Amrutanjan Limited and changed its name to Amrutanjan Health Care Limited in 2007. Amrutanjan Health Care Limited was founded in 1893 and is based in Chennai, India.
1. OTC Products-This segment manufactures over the counter products related to pain management, congestion management, and hygiene. 2. Beverages-This segment produces fruit juices and oral rehydration drinks. 3. Others-This segment operates pain management center. 4. Unallocated Assets-0
1. OTC Products (Excl. Women Hygiene)-65.3% 2. Women's Hygiene & Personal Care-27.8% 3. Beverages-6.3% 4. Others-0.6%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Glaxosmithkline Pharmaceuticals Ltd. | ₹44,982 Cr | 43.4 | 48.91% | ₹1,184 Cr | +3.3% |
| Alembic Pharmaceuticals Limited (Aplltd) | ₹20,245 Cr | 30.5 | 12.36% | ₹2,603 Cr | +11.7% |
| Bliss Gvs Pharma Ltd. | ₹6,817 Cr | 53.9 | 11.60% | ₹313 Cr | +426.3% |
| Zota Health Care Ltd | ₹4,585 Cr | n/m | -16.05% | ₹199 Cr | -15.1% |
| Amrutanjan Health Care Ltd. | ₹1,467 Cr | 25.3 | 16.62% | ₹135 Cr | -28.1% |
| Jenburkt Pharmaceuticals Ltd. | ₹433 Cr | 12.5 | 18.84% | — | -11.8% |
| Sat Kartar Life Limited | ₹256 Cr | 15.7 | 25.30% | — | — |
| Vista Pharmaceuticals Ltd. | ₹40 Cr | n/m | -10.82% | — | -37.1% |
| Welcure Drugs & Pharmaceuticals | ₹23 Cr | n/m | -5.50% | — | -64.2% |
Listed by market capitalisation. Ratios are shown for context only.
Amrutanjan Health Care Ltd. is trading at ₹507.50, with a market capitalisation of ₹1,467 Cr.
Amrutanjan Health Care Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Non-Prescription Drugs).
Amrutanjan Health Care Ltd. has a P/E of 25.3 and a return on equity of 16.62%.
Amrutanjan Health Care Ltd. is listed on the BSE under the scrip code 590006.
Amrutanjan Health Care Ltd.'s share price is down 28.1% over one year and up 3.4% over three months. Its 52-week range is ₹476.50 to ₹725.60.
In Q2 FY27, Amrutanjan Health Care Ltd. reported revenue of ₹135 Cr and net profit of ₹17 Cr, with basic EPS of ₹5.98 (standalone, parsed from the company's exchange filing).
Amrutanjan Health Care Ltd. reported revenue of ₹135 Cr in Q2 FY27, up 14.9% from ₹118 Cr in Q2 FY26 and up 31.3% from ₹103 Cr in Q1 FY27.
Promoters held 46.52% of Amrutanjan Health Care Ltd.'s shares as of Sept 2026, unchanged from Sept 2025.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.